CNBC’s Charlotte Reed reports on the setback suffered by Sanofi and GSK in the development of their Covid-19 vaccine, now not expected until the latter part of 2021.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund — Russia’s sovereign wealth fund — discusses the development of Avifavir, a drug the country has approved to be delivered to hospitals for use in Covid-19 patients from June.
Michael O’Sullivan, former CIO of international wealth management at Credit Suisse and author of “The Levelling,” discusses the economic impact of the coronavirus crisis.